Aaron P Mitchell1, Jason S Rotter2, Esita Patel3, Daniel Richardson3,4,5, Stephanie B Wheeler2,3,5, Ethan Basch2,4,5, Daniel A Goldstein2,6. 1. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Health Policy and Management, University of North Carolina Gillings School of Global Public Health, Chapel Hill. 3. Cecil G. Sheps Center for Health Services Research, Chapel Hill, North Carolina. 4. Department of Hematology/Oncology, University of North Carolina at Chapel Hill School of Medicine. 5. Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. 6. Davidoff Cancer Center, Rabin Medical Center, Petach Tikvah, Israel.
Abstract
IMPORTANCE: Significant controversy exists regarding whether physicians factor personal financial considerations into their clinical decision making. Within oncology, several reimbursement policies may incentivize physicians to increase health care use. OBJECTIVE: To evaluate whether the financial incentives presented by oncology reimbursement policies affect physician practice patterns. EVIDENCE REVIEW: Studies evaluating an association between reimbursement incentives and changes in reimbursement policy on oncology care delivery were reviewed. Articles were identified systematically by searching PubMed/MEDLINE, Web of Science, Proquest Health Management, Econlit, and Business Source Premier. English-language articles focused on the US health care system that made empirical estimates of the association between a measurement of physician reimbursement/compensation and a measurement of delivery of cancer treatment services were included. The Risk of Bias in Non-Randomized Studies of Interventions tool was used to assess risk of bias. There were no date restrictions on the publications, and literature searches were finalized on February 14, 2018. FINDINGS: Eighteen studies were included. All were observational cohort studies, and most had a moderate risk of bias. Heterogeneity of reimbursement policies and outcomes precluded meta-analysis; therefore, a qualitative synthesis was performed. Most studies (15 of 18 [83%]) reported an association between reimbursement and care delivery consistent with physician responsiveness to financial incentives, although such an association was not identified in all studies. Findings consistently suggested that self-referral arrangements may increase use of radiotherapy and that profitability of systemic anticancer agents may affect physicians' choice of drug. Findings were less conclusive as to whether profitability of systemic anticancer therapy affects the decision of whether to use any systemic therapy. CONCLUSIONS AND RELEVANCE: To date, this study is the first systematic review of reimbursement policy and clinical care delivery in oncology. The findings suggest that some oncologists may, in certain circumstances, alter treatment recommendations based on personal revenue considerations. An implication of this finding is that value-based reimbursement policies may be a useful tool to better align physician incentives with patient need and increase the value of oncology care.
IMPORTANCE: Significant controversy exists regarding whether physicians factor personal financial considerations into their clinical decision making. Within oncology, several reimbursement policies may incentivize physicians to increase health care use. OBJECTIVE: To evaluate whether the financial incentives presented by oncology reimbursement policies affect physician practice patterns. EVIDENCE REVIEW: Studies evaluating an association between reimbursement incentives and changes in reimbursement policy on oncology care delivery were reviewed. Articles were identified systematically by searching PubMed/MEDLINE, Web of Science, Proquest Health Management, Econlit, and Business Source Premier. English-language articles focused on the US health care system that made empirical estimates of the association between a measurement of physician reimbursement/compensation and a measurement of delivery of cancer treatment services were included. The Risk of Bias in Non-Randomized Studies of Interventions tool was used to assess risk of bias. There were no date restrictions on the publications, and literature searches were finalized on February 14, 2018. FINDINGS: Eighteen studies were included. All were observational cohort studies, and most had a moderate risk of bias. Heterogeneity of reimbursement policies and outcomes precluded meta-analysis; therefore, a qualitative synthesis was performed. Most studies (15 of 18 [83%]) reported an association between reimbursement and care delivery consistent with physician responsiveness to financial incentives, although such an association was not identified in all studies. Findings consistently suggested that self-referral arrangements may increase use of radiotherapy and that profitability of systemic anticancer agents may affect physicians' choice of drug. Findings were less conclusive as to whether profitability of systemic anticancer therapy affects the decision of whether to use any systemic therapy. CONCLUSIONS AND RELEVANCE: To date, this study is the first systematic review of reimbursement policy and clinical care delivery in oncology. The findings suggest that some oncologists may, in certain circumstances, alter treatment recommendations based on personal revenue considerations. An implication of this finding is that value-based reimbursement policies may be a useful tool to better align physician incentives with patient need and increase the value of oncology care.
Authors: Aaron P Mitchell; Alan C Kinlaw; Sharon Peacock-Hinton; Stacie B Dusetzina; Hanna K Sanoff; Jennifer L Lund Journal: Oncologist Date: 2019-10-14
Authors: Douglas Grossman; Nwanneka Okwundu; Edmund K Bartlett; Michael A Marchetti; Megan Othus; Daniel G Coit; Rebecca I Hartman; Sancy A Leachman; Elizabeth G Berry; Larissa Korde; Sandra J Lee; Menashe Bar-Eli; Marianne Berwick; Tawnya Bowles; Elizabeth I Buchbinder; Elizabeth M Burton; Emily Y Chu; Clara Curiel-Lewandrowski; Julia A Curtis; Adil Daud; Dekker C Deacon; Laura K Ferris; Jeffrey E Gershenwald; Kenneth F Grossmann; Siwen Hu-Lieskovan; John Hyngstrom; Joanne M Jeter; Robert L Judson-Torres; Kari L Kendra; Caroline C Kim; John M Kirkwood; David H Lawson; Philip D Leming; Georgina V Long; Ashfaq A Marghoob; Janice M Mehnert; Michael E Ming; Kelly C Nelson; David Polsky; Richard A Scolyer; Eric A Smith; Vernon K Sondak; Mitchell S Stark; Jennifer A Stein; John A Thompson; John F Thompson; Suraj S Venna; Maria L Wei; Susan M Swetter Journal: JAMA Dermatol Date: 2020-09-01 Impact factor: 10.282
Authors: Aaron P Mitchell; Akriti Mishra Meza; Katherine S Panageas; Allison Lipitz-Snyderman; Peter B Bach; Michael J Morris Journal: J Natl Cancer Inst Date: 2022-03-08 Impact factor: 11.816
Authors: Christopher R Manz; Angela C Tramontano; Hajime Uno; Ravi B Parikh; Justin E Bekelman; Deborah Schrag Journal: JAMA Netw Open Date: 2022-09-01
Authors: David I Pryor; Jarad M Martin; Jeremy L Millar; Heather Day; Wee Loon Ong; Marketa Skala; Liesel M FitzGerald; Benjamin Hindson; Braden Higgs; Michael E O'Callaghan; Farhan Syed; Amy J Hayden; Sandra L Turner; Nathan Papa Journal: JAMA Netw Open Date: 2021-11-01